*5.1.1.4 Insulin-like growth factor (iLGF)*

 The recombinant human insulin-like growth factor-1 (rhIGF-1) is also called mecasermin (International Nonproprietary Name (INN)). Children who are very short of their age are the target group of the product [53] and are FDA approved for the mentioned condition called severe primary Insulin IGF-1 deficiency under the trade name of INCRELEX. The FDA approval (in Aug, 2005) was based on five clinical trials of the drug (subcutaneously injected), of which four were open-label studies and one was double-blinded and placebo-controlled. The integrated results, followed up each year for 8 years, showed a considerable increase in height velocity (HV) with reference to pre-treatment [54]. HV is calculated between consecutive annual study visits as the difference in height, divided by the difference in age [55].
